Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
IMMUNOMEDICS INC (IMMU)
|
Add to portfolio |
|
|
|
| Price: |
$87.86
| | Metrics |
| OS: |
231.1
|
M
| |
-60
|
% ROE
|
| Market cap: |
$20.3
|
B
| |
-427
|
% ROIC
|
|
Net cash:
|
$976
|
M
| |
$4.22
|
per share
|
|
EV:
|
$19.3
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($309)
|
M
| |
|
|
|
EBIT
|
($313)
|
M
| |
|
|
| EPS |
($1.74)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 | Jun-30-15 | Jun-30-14 | Jun-30-13 | Jun-30-12 |
| Revenues | 0.3 | 2.2 | 3.1 | 3.2 | 5.7 | 9.0 | 5.0 | 32.7 |
| Revenue growth | | -30.3% | -4.4% | -42.8% | -37.5% | 82.2% | -84.8% | 122.5% |
| Cost of goods sold | 0.0 | 0.6 | 0.5 | 1.2 | 0.3 | 1.5 | 0.4 | 0.4 |
| Gross profit | 0.3 | 1.5 | 2.6 | 2.1 | 5.4 | 7.5 | 4.6 | 32.3 |
| Gross margin | 100.0% | 71.6% | 84.4% | 64.1% | 95.3% | 83.1% | 92.1% | 98.7% |
| Sales and marketing | 26.5 | 6.8 | 0.9 | 1.0 | 0.8 | 1.1 | 0.8 | 0.8 |
| Research and development | 254.9 | 99.3 | 51.8 | 53.5 | 41.7 | 33.7 | 28.4 | 24.3 |
| General and administrative | 43.8 | 36.5 | 29.1 | 6.6 | 9.1 | 8.3 | 6.2 | 5.8 |
| EBIT | -324.8 | -134.4 | -79.1 | -59.0 | -46.2 | -35.6 | -30.7 | 1.4 |
| EBIT margin | -110114.6% | -6234.2% | -2560.4% | -1825.0% | -817.6% | -393.5% | -617.8% | 4.4% |
| Pre-tax income | -357.3 | -273.7 | -153.2 | -64.2 | -48.1 | -35.5 | -11.4 | 1.5 |
| Income taxes | 0.0 | 0.2 | 0.0 | -5.1 | 0.1 | 0.0 | 0.0 | 0.2 |
| Tax rate | 0.0% | | | 7.9% | | | | 14.2% |
| Net income | -357.2 | -273.8 | -153.2 | -59.0 | -48.0 | -35.4 | -11.4 | 1.4 |
| Net margin | -121081.4% | -12701.2% | -4956.1% | -1825.9% | -849.1% | -391.8% | -229.4% | 4.2% |
| |
| Diluted EPS | ($1.84) | ($1.78) | ($1.47) | ($0.62) | ($0.51) | ($0.42) | ($0.15) | $0.02 |
| Shares outstanding (diluted) | 193.6 | 153.5 | 104.5 | 94.8 | 93.3 | 84.6 | 78.0 | 76.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|